Integer Holdings (ITGR)
(Delayed Data from NYSE)
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$132.43 USD
+3.19 (2.47%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $132.54 +0.11 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth C Momentum B VGM
Zacks News
GE Healthcare (GEHC), MedQuest Partner to Boost Imaging Field
by Zacks Equity Research
GE Healthcare (GEHC) collaborates with MedQuest to optimize outpatient imaging networks. With AI capabilities from GE Healthcare, MedQuest is likely to provide better solutions in the imaging space.
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
by Zacks Equity Research
ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies (COO), Fulgent Unite to Boost Genetic Testing
by Zacks Equity Research
Cooper Companies (COO) collaborates with Fulgent Genetics to boost newborn genetic screenings. CBR by Cooper Surgical is likely to provide a variety of genetic testing options to its families.
Here's Why You Should Add HealthEquity (HQY) to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Integer (ITGR) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Integer (ITGR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now
by Zacks Equity Research
The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.
Fresenius Medical (FMS) Gets FDA Nod for New Hemodialysis System
by Zacks Equity Research
Fresenius Medical (FMS) receives an FDA nod for its new 5008X Hemodialysis System that aims to provide better dialysis therapy for kidney patients in the United States.
DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand
by Zacks Equity Research
Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
Integer (ITGR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Launches One+ Real-time CGM System in Europe
by Zacks Equity Research
DexCom (DXCM) unveils its new CGM system, Dexcom ONE+, which is set to provide easy and effective care to diabetic patients.
McKesson (MCK) Beats on Q3 Earnings, Raises FY24 EPS View
by Zacks Equity Research
McKesson's (MCK) third-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Microbot Medical (MBOT) Files IDE to Start Human Clinical Study
by Zacks Equity Research
Microbot Medical (MBOT) files an IDE with the FDA, approval of which will enable the company to proceed with its human clinical study in the United States.
Here's Why Integer (ITGR) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings
by Zacks Equity Research
Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.
Hologic (HOLX) Introduces Genius Digital Diagnostics System
by Zacks Equity Research
Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Philips (PHG) Receives FDA Class 1 Recall for BrightView SPECT
by Zacks Equity Research
Philips (PHG) receives an FDA Class 1 recall for BrightView imaging systems.
PacBio's (PACB) New Kits to Boost Its Revio Sequencing System
by Zacks Equity Research
PacBio's (PACB) new library preparation kits are likely to boost Revio's long-read sequencing systems by reducing cost and workflow time.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
InspireMD's (NSPR) CE Mark Recertification to Boost CGuard EPS
by Zacks Equity Research
InspireMD's (NSPR) CE Mark Recertification under MDR is likely to help the company boost the CGuard EPS for carotid artery revascularization care along with advancing with new products.
Modular Medical (MODD) Pairing Technology Issued New U.S. Patent
by Zacks Equity Research
Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.